Biomarkers and methods for treating NSCLC
JP2025520098A5Pending Publication Date: 2026-06-03ティージェイバイオファーマ(シャンハイ)カンパニーリミテッド +1
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- ティージェイバイオファーマ(シャンハイ)カンパニーリミテッド
- Filing Date
- 2023-05-26
- Publication Date
- 2026-06-03
AI Technical Summary
Technical Problem
Current treatments for non-small cell lung cancer (NSCLC) are less effective due to the disease's resistance to chemotherapy and the need for improved patient selection and prognosis methods.
Method used
A method for treating NSCLC by determining the level of CD73 in a subject and evaluating the likelihood of response to a combination treatment of a CD73 antagonist and a PD1/PD-L1 antagonist based on CD73 levels, followed by administering the treatment if beneficial.
Benefits of technology
This approach enhances the effectiveness of treatment by identifying subjects likely to benefit from the combination therapy, improving overall survival and response rates in NSCLC patients.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0000_ABST
Abstract
Biomarkers and methods for the treatment of non-small cell lung cancer (NSCLC). Biomarkers related to patient selection and prognosis, and diagnostic kits for analyzing the above biomarkers. In some embodiments of the methods of the present application, the CD73 antagonist of the above combination treatment is a CD73 antibody. In some embodiments, the CD73 antibody is selected from the group consisting of polyclonal antibodies, monoclonal antibodies, Fab, scFv, diabody, triabody, minibody, VHH and sdAb.
Need to check novelty before this filing date? Find Prior Art